Last reviewed · How we verify
NCT06629740
A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication
NA trial testing Measurements with a eHealth system in Substance Use Disorder (SUD) in 34 participants. Completed in 18 March 2025.
17 March 2025
Quick facts
| Lead sponsor | Kontigo Care AB |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 34 |
| Start date | 1 November 2024 |
| Primary completion | 17 March 2025 |
| Estimated completion | 18 March 2025 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Measurements with a eHealth system
Conditions studied
- Substance Use Disorder (SUD) — all drugs for Substance Use Disorder (SUD) →
Sponsor
Kontigo Care AB
Who can join
Adults 18 to 55, any sex, with Substance Use Disorder (SUD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines. Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines. The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Detecting benzodiazepine use through induced eye convergence inability with a smartphone app: a proof-of-concept study.
Kuijpers KWK, Hämäläinen MD, Zetterström A, Winkvist M, et al · · 2025 · PMID 40520217 · DOI 10.3389/fdgth.2025.1584716
Verify or expand the search:
- PubMed search for NCT06629740
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Use Disorder (SUD)
Currently open trials in the same condition.
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07503067 — Identifying Substance Use Consequences · recruiting
- NCT06790641 — Pathways to Perinatal Mental Health Equity · NA · recruiting
- NCT07433985 — California MEPS Hub · NA · recruiting
- NCT07214467 — Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder · NA · recruiting
Other Kontigo Care AB trials
Trials by the same sponsor.
- NCT05737550 — An Explorative Pilot Study of a New Mobile Phone Application Measuring Eye Parameters of Eyes in Patients With SUD · NA · completed
- NCT05731999 — A First Study in Healthy Volunteers of a New Mobile Phone Application Measuring the Eyes Before and After Medication · NA · completed
- NCT03195894 — Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06629740 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kontigo Care AB
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06629740.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing